You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
The test is the first capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from blood cultures containing Gram-negative rods in less than 90 minutes.
The US Food and Drug Administration has granted 510(K) clearance for AdvanDx's 90-minute Yeast Traffic Light PNA FISH protocol for detecting Candida yeast.
AdvanDx received 510(k) clearance for 90-minute versions of its Escherichia coli/Pseudomonas aeruginosa and EK/P. aeruginosa diagnostic tests.
The new version of the peptide nucleic acid fluorescence in situ hybridization test takes 90 minutes instead of 2.5 hours for conventional tests.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.